congestive heart failure: turning failure into success · trial n parameter monitored impact on hf...
TRANSCRIPT
![Page 1: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/1.jpg)
Congestive Heart Failure: Turning Failure Into Success
Wednesday, Feb 21, 2018
![Page 2: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/2.jpg)
Welcome & Opening Remarks
Robert T. Smith, MD, FACP
![Page 3: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/3.jpg)
Introduction of Conference Theme & SpeakerBrian Schwartz, MD, FACP, FACC, FSCAI
Kettering Heart and Vascular Medical Director
![Page 4: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/4.jpg)
Keynote SpeakerJaved Butler, MD, PhD
Heart Failure 2018: Where Are We and Where Are We Going!
Evolution to HFpEF
![Page 5: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/5.jpg)
Q&A With Dr. ButlerRobert T. Smith, MD, FACP
![Page 6: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/6.jpg)
Break, Vendor Fair, and Refreshments
![Page 7: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/7.jpg)
Understanding HFrEF/Advanced HF
Deepthi Mosali, MD, FACC
![Page 8: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/8.jpg)
Mechanisms of HFrEF
![Page 9: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/9.jpg)
![Page 10: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/10.jpg)
![Page 11: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/11.jpg)
![Page 12: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/12.jpg)
![Page 13: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/13.jpg)
Effects of persistent SNS activation
![Page 14: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/14.jpg)
RAAS System activation
![Page 15: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/15.jpg)
Natriuretic Peptides
![Page 16: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/16.jpg)
Beta-Adrenergic signaling
![Page 17: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/17.jpg)
Excitation-Contraction coupling
![Page 18: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/18.jpg)
![Page 19: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/19.jpg)
Changes in the biology of the failing heart
![Page 20: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/20.jpg)
![Page 21: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/21.jpg)
![Page 22: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/22.jpg)
![Page 23: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/23.jpg)
![Page 24: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/24.jpg)
![Page 25: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/25.jpg)
![Page 26: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/26.jpg)
Is that it ?
• Lot of patients with so called “stable” chronic ds are indeed not stable with most patients exhibiting elevated cardiac biomarkers such as troponin reflective of continued cardiomyocyte necrosis or loss. This is reflective of a underlying dynamic process contributing to ds progression
![Page 27: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/27.jpg)
Mechanisms that drive LV Dysfunction: Intrinsic1. Cardiac Apoptosis – cardiomyocyte loss is the hallmark of HFrEF. Limited capacity for
self renewal so gradual loss f functional units through cell death leads to ds progression
2. Mitochondrial abnormalities: abnormalities of ATP synthesis and excess production of ROS.
3. Impaired intracellular calcium cycling (calcium signalling plays an important role in modulating systolic and diastolic function and in regulating excitation-contraction coupling. Abnormalities of intracellular calcium handling such a reduced SERCA activity, impaired phosphorylation of phospholamban and ryanodine channel leading to calcium leaks. This cacause calcium overload, arrhythmias, cardiomyocyte dysfunction and death
4. Wall stress (Laplace’s law, increased MVO2)
5. Fibrosis and cardiomyocyte hypertrophy (reactive interstitial fibrosis, reduced capillary density, increased oxygen diffusion all causing hypoxia and increasing LV stiffness and contributing to LV dysfunction
![Page 28: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/28.jpg)
Physiology
•Hemodynamics and PV loops
![Page 29: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/29.jpg)
![Page 30: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/30.jpg)
![Page 31: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/31.jpg)
![Page 32: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/32.jpg)
![Page 33: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/33.jpg)
![Page 34: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/34.jpg)
![Page 35: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/35.jpg)
![Page 36: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/36.jpg)
![Page 37: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/37.jpg)
![Page 38: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/38.jpg)
Therapeutics
• Targeting the Neuroharmonal pathways
• Treating at the “periphery”
• Despite blockade of the “maladaptive” processes there is still progression of disease
![Page 39: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/39.jpg)
![Page 40: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/40.jpg)
![Page 41: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/41.jpg)
Mechanism of ARNI
![Page 42: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/42.jpg)
![Page 43: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/43.jpg)
![Page 44: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/44.jpg)
Biomarkers
![Page 45: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/45.jpg)
![Page 46: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/46.jpg)
Progression to Stage D or Advanced HF
![Page 47: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/47.jpg)
Advanced HF is the presence of progressive and/or persistent severe symptoms of heart failure despite optimized medical, surgical and device therapy
![Page 48: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/48.jpg)
HFrEF now becomes a systemic ds
• Passive liver congestion, ascites
• Bone marrow dysfunction and anemia
• Endothelial dysfunction
• Sleep disordered breathing
• Renal dysfunction
• Skeletal muscle abnormalities
• Persistent venous congestion causes inflammation with elevated biomarkers and systemic inflammation
![Page 49: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/49.jpg)
Who Has Advanced Heart Failure? Definition and Epidemiology
Congestive Heart FailureVolume 17, Issue 4, pages 160-168, 21 JUL 2011 DOI: 10.1111/j.1751-7133.2011.00246.xhttp://onlinelibrary.wiley.com/doi/10.1111/j.1751-7133.2011.00246.x/full#f1
![Page 50: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/50.jpg)
A depiction of the clinical course of heart failure with associated types and intensities of available therapies.
Larry A. Allen et al. Circulation. 2012;125:1928-1952
Copyright © American Heart Association, Inc. All rights reserved.
![Page 51: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/51.jpg)
ACC/AHA/HFSA focused updated guidelines for HF
![Page 52: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/52.jpg)
Impact of recurrent heart failure hospitalization on mortality. Median survival (50% mortality) with 95% confidence limits in patients with heart failure after each heart failure hospitalization. (From Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007;154(2):262;)
![Page 53: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/53.jpg)
![Page 54: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/54.jpg)
Who Has Advanced Heart Failure? Definition and Epidemiology
Congestive Heart FailureVolume 17, Issue 4, pages 160-168, 21 JUL 2011 DOI: 10.1111/j.1751-7133.2011.00246.xhttp://onlinelibrary.wiley.com/doi/10.1111/j.1751-7133.2011.00246.x/full#f3
![Page 55: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/55.jpg)
• END OF PRESENTATION
![Page 56: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/56.jpg)
![Page 57: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/57.jpg)
![Page 58: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/58.jpg)
![Page 59: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/59.jpg)
![Page 60: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/60.jpg)
![Page 61: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/61.jpg)
![Page 62: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/62.jpg)
Clinical Assessment
![Page 63: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/63.jpg)
Who Has Advanced Heart Failure? Definition and Epidemiology
Congestive Heart FailureVolume 17, Issue 4, pages 160-168, 21 JUL 2011 DOI: 10.1111/j.1751-7133.2011.00246.xhttp://onlinelibrary.wiley.com/doi/10.1111/j.1751-7133.2011.00246.x/full#f2
![Page 64: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/64.jpg)
![Page 65: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/65.jpg)
Virtual Heart Failure Clinic“Smart” HF management
Sateesh Kesari MD FACC
![Page 66: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/66.jpg)
Disclosures
• I have no current or past relationships with commercial entities
• Speaking fees for current program:• I have received no speaker’s fee for this learning activity
• Acknowledgements: Slides courtesy of• Abbott/ST Jude
• Medtronic
• Boston Scientific
![Page 67: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/67.jpg)
Scope of the presentation
• Financial and clinical burden of heart failure
• Tele monitoring
• Device monitoring
• Hemodynamic monitoring
![Page 68: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/68.jpg)
Scope of the presentation
• Financial and clinical burden of heart failure
• Tele monitoring
• Device monitoring
• Hemodynamic monitoring
![Page 69: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/69.jpg)
*Study projections assumes HF prevalence remains constant and continuation of current hospitalization practices
Heart Failure is a Growing Economic Burden
HOSPITALIZATIONS AND READMISSIONS COSTS
> 1,100,000hospitalizations
for HF1
> 3,000,000hospitalizations
include HF as a contributor.2
Total medical costs for HF are projected to
increase to $70B
by 2030, a 2x increase from 2013.*
50% of the costs are
attributed to hospitalization.6~5 days
average length of hospital stay3
~25%all-cause readmission within 30 days; ~50% within 6 months.4,5
6925267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.
Despite advances in medical therapies to treat heart failure, the hospitalization rate has not changed significantly from 2000. As a result, heart failure continues to be a
MAJOR DRIVER OF OVERALL HEALTH CARE COSTS.
UNITED STATES
1. CDC NCHS National Hospital Discharge Survey, 2000-10.
2. Blekcer et al. J Am Coll Cardiol, 2013.
3. Yancy et al. J Am Coll Cardiol, 2006.
4. Wxler DJ, et al. Am Heart J, 2001.
5. Krumholz HM, et al. Circ Cardiovas Qual Outcomes, 2009.
6. Yancy CW, et al. Circulation, 2013.
![Page 70: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/70.jpg)
Heart Failure is a Growing Global Clinical Burden• UNITED STATES
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use. 70
1. AHA 2016 Statistics at a Glance, 2016.
2. Krumholz HM, et al. Circ Cardiovas Qual Outcomes, 2009.
3. Heidenreich PA, et al. Circ Heart Failure, 2013.
HIGH INCIDENCE, HIGH PREVALENCE, AND POOR PROGNOSISdespite advances in the treatment of heart failure over the past few decades.
PREVALENCE 2.2%Prevalence1
5.7mHF patients1
Projected to increase to > 8M people ≥ 18 years of age with HF by 20301
INCIDENCE915,000
people ≥ 45 years of age are newly diagnosed each year with HF.1
MORBIDITY AND MORTALITY
For AHA/ACC stage C/D patients diagnosed with HF:
50% Readmitted within
6 months.2
50% Will die within
5 years.3
![Page 71: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/71.jpg)
Long-term Mortality Risk Increases with Multiple Hospitalizations
71
• Setoguchi S, Stevenson LW, Schneeweiss S, Am Heart J, 2007;154:260-264.
Mortality Survival
![Page 72: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/72.jpg)
• EACH EVENT ACCELERATES DOWNWARD SPIRAL OF MYOCARDIAL FUNCTION
With each subsequent HF-related admission, the patient leaves the hospital with a further decrease in cardiac function.
THE GOAL:Maintain fluid volume to avoid
acute decompensation and hospitalization
HF HOSPITALIZATION is a valid endpoint for measuring
decompensation
Goal of Heart Failure Management: SLOW DISEASE PROGRESSION BY PREVENTING DECOMPENSATION
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use. 72Gheorghiade MD, et al. Am J. Cardiol, 2005.
Acute Event
TIME
MYO
CA
RD
IAL
FUN
CTI
ON
![Page 73: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/73.jpg)
Scope of the presentation
• Financial and clinical burden of heart failure
• Tele monitoring
• Device monitoring
• Hemodynamic monitoring
![Page 74: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/74.jpg)
Monitored days of a HF patient.
Lynn Stevenson et al
![Page 75: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/75.jpg)
Parameters
• Daily Impedence
• Heart rate variability
• Patient Activity
• Biventricular pacing < 90%
• Ventricular pacing (ICD)
• Night time HR
• Atrial fibrillation/AT/AFL
• Ventricular tachycardia/ICD shocks
![Page 76: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/76.jpg)
Remote monitoring HF trialsTRIAL N PARAMETER
MONITOREDIMPACT ON
HF HOSPITALIZATION JOURNAL
TELE-HF1 1,653 Signs/symptoms, daily weights None The New England Journal of Medicine, 2010
TIM-HF2 710 Signs/symptoms, daily weights None Circulation, 2011
TEN-HMS3 426 Signs/symptoms, daily weights, BP,
nurse telephone support None Journal of the American College of Cardiology, 2005
BEAT-HF4 1,437 Signs/symptoms, daily weights, nurse communications None American Heart Association, 2016
INH5 715 Signs/symptoms, telemonitoring, nurse coordinated DM None Circulation Heart Failure, 2012
DOT-HF6 335 Intrathoracic impedance with patient alert Increased Circulation, 2011
Optilink7 1,002 Intrathoracic impedance None European Journal of Heart Failure, 2011
REM-HF8 1,650 Remote monitoring via ICD, CRT-D or CRT-P None European Society of Cardiology,
2017
MORE CARE9 865 Remote monitoring of advanced
diagnostics via CRT-D None European Journal of Heart Failure, 2016
Total 8,793
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use. 76
• 1. Chaudhry SI, et al. N Engl J Med, 2010.
• 2. Koehler F, et al. Circulation, 2011.
• 3. Cleland JG, et al. J Am Coll Cardiol, 2005.
• 4. Ong MK, et al. JAMA Intern Med, 2016.
• 5. Angermann DE, et al. Circ Heart Fail, 2012.
• 6. van Veldhuisen DJ, et al. Circulation, 2011.
• 7. Brachmann J, et al. Eur J Heart Fail, 2011.
• 8. Cowie MR, ESC, 2016.
• 9. Boriani G, et al. Eur J Heart Fail, 2016.
MULTIPLE TRIALS, > 8,500 PATIENTS:No reduction in HF hospitalization
![Page 77: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/77.jpg)
Impedence
![Page 78: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/78.jpg)
Impedence
![Page 79: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/79.jpg)
Impedence cases
-Drop in Impedence-Preceded by AT/AF-High Ventricular rates-Loss of CRT pacing
-Drop in impedence-followed by VT storm
Example # 2Example # 1
![Page 80: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/80.jpg)
Device monitoring with multiple paramaters
• Heart Logic
• Multisense trial
• Manage HF trial
• Beacon HF system
• Partners HF trial
![Page 81: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/81.jpg)
Multisense trial for HeartLogic
JACC: Heart Failure vol 5. no. march 2017;216-25
![Page 82: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/82.jpg)
HeartLogic index trend in pts with and without HFE
JACC: Heart Failure vol 5. no. march 2017;216-25
![Page 83: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/83.jpg)
Disclosures
![Page 84: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/84.jpg)
+ DiagnosticTWO diagnostic criteria met
❑ Fluid Index ≥ 100
❑ Fluid Index ≥ 60
❑ Avg. Activity < 1 hr over 1
week
❑ Avg night HR > 85 bpm for 7
consecutive days
❑ HRV < 60 ms for 7
consecutive days
❑ % V pacing < 90% for 5 of 7
days
❑ One or more shocks
❑ AF > 6 hrs on at least one day
in pts without persistent AF
❑ AF > 24 hrs & VR-AF > 90
bpm
N = 694 patients
Monthly Evaluations =
5693
HF Events = 78
PARTNERS-HF: COMBINED DIAGNOSTICS
Whellan DJ, et al. J Am Coll Cardiol. 2010;55:1803-1810.
Partners HF study showed monthly review of HF diagnostic data could have identified
patients at higher risk of HF hospitalizations within the subsequent month.
OptiVol/HFMR identified patients were 5.5 times as likely to be hospitalized within 30
days
84 Beacon Heart Failure Management Service | Division of Medtronic Care Management Services | Confidential Information
![Page 85: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/85.jpg)
85Beacon Heart Failure Management Service | Division of Medtronic Care Management Services |Confidential Information
TRIAGECOMBINING DEVICE DIAGNOSTICS & EXTERNAL BIOMETRICS
BROAD CLINICAL INPUTS
LON
GIT
UD
INA
L P
AT
IEN
T D
ATA
BIOMETRICS
SYMPTOMS
High Risk Markers Identified,
Follow up 72 hours
Limited High Risk Markers
Identified,Follow Up
1 week
Low Risk,Routine Clinical Follow
Up
Multiple High Risk Markers Identified,
Follow up 24 hours
BEACON HF MGMTREPORT
RISK
STRA
TIFICA
TION
EXPERT CHFN* ASSESSMENT
OptiVol + Parameters
Symptom Acuity
Care Plan Adherence
Clinical Intervention
Ongoing Education
CHFN Analysis
ROBUST RISK ANALYSIS
ACTIONABLE REPORTING
!DEVICEDIAGNOSTICS
IP/ER EVENT
STATUS
*Certified Heart Failure Nurse, certified by the American Association of Heart Failure Nurses
![Page 86: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/86.jpg)
Device DiagnosticsCOMBINING DYNAMIC DATA TO PROVIDE ADVANCED INSIGHTS
Patients with a high risk score were 10 times more likely to have a heart failure event in the next 30 days than those with a low risk score1
% m
on
thly
eva
luat
ion
s w
ith
HF
ho
spit
aliz
atio
ns
in n
ext
30
day
s
Days after diagnostic evaluation
10xGreater Risk
Diagnostic
Parameters
Bayesian
Combination
Probability / Likelihood Off..
Dynamic Algorithm1
1 Cowie MR, Sarkar S, Koehler J, et al. Eur Heart J. 2013 Aug;34(31):2472-80
Beacon Heart Failure Management Service | Division of Medtronic Care Management Services | Confidential Information86
![Page 87: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/87.jpg)
Scope of the presentation
• Burden of heart failure with financial and clinical impact
• Tele monitoring
• Device monitoring
• Hemodynamic monitoring
![Page 88: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/88.jpg)
Reactive and Inexact
Current Parameters for Managing HF are Reactive and Inexact
88• Adamson PB, et al. Curr Heart Fail Reports, 2009.
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.
Hemodynamically Stable Decompensation
HOSPITALIZATION
Autonomic Adaptation
Time Preceding Hospitalization (Days)
-30 -20 -10 0
Transthoracic Impedance
CHANGE
Filling Pressure
INCREASE
Weight Change
Symptoms
Presymptomatic Congestion
![Page 89: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/89.jpg)
Proactive and Actionable
Monitoring for Increased Filling Pressures is Proactive and Actionable, and Predictive of Acute Decompensation
8925267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.• Adamson PB, et al. Curr Heart Fail Reports, 2009.
Hemodynamically Stable Decompensation
HOSPITALIZATION
Autonomic Adaptation
Time Preceding Hospitalization (Days)
-30 -20 -10 0
Transthoracic Impedance
CHANGE
Filling Pressure
INCREASE
Weight Change
Symptoms
Presymptomatic Congestion
Reactive and Inexact
![Page 90: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/90.jpg)
Monitoring Pulmonary Artery Pressures,Proactive and Actionable
9025267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.• Adamson PB, et al. Curr Heart Fail Reports, 2009.
GAIN IN TIME
Proactive and Actionable
Reactive and Inexact
Hemodynamically Stable Decompensation
HOSPITALIZATION
Autonomic Adaptation
Time Preceding Hospitalization (Days)
-30 -20 -10 0
Transthoracic Impedance
CHANGE
Filling Pressure
INCREASE
Weight Change
Symptoms
Presymptomatic Congestion
Hemodynamic Congestion
Clinical Congestion
![Page 91: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/91.jpg)
Monitoring Pulmonary Artery Pressures,Proactive and Actionable
9125267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.• Adamson PB, et al. Curr Heart Fail Reports, 2009.
GAIN IN TIME
Proactive and Actionable
Reactive and Inexact
Hemodynamically Stable Decompensation
HOSPITALIZATION
Autonomic Adaptation
Time Preceding Hospitalization (Days)
-30 -20 -10 0
Transthoracic Impedance
CHANGE
Filling Pressure
INCREASE
Weight Change
Symptoms
Presymptomatic Congestion
Hemodynamic Congestion
Clinical Congestion
Physical examTele monitoring
![Page 92: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/92.jpg)
Monitoring Pulmonary Artery Pressures,Proactive and Actionable
9225267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.• Adamson PB, et al. Curr Heart Fail Reports, 2009.
GAIN IN TIME
Proactive and Actionable
Reactive and Inexact
Hemodynamically Stable Decompensation
HOSPITALIZATION
Autonomic Adaptation
Time Preceding Hospitalization (Days)
-30 -20 -10 0
Transthoracic Impedance
CHANGE
Filling Pressure
INCREASE
Weight Change
Symptoms
Presymptomatic Congestion
Hemodynamic Congestion
Clinical Congestion
Physical examTele monitoringDevice monitoring
![Page 93: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/93.jpg)
Monitoring Pulmonary Artery Pressures,Proactive and Actionable
9325267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.• Adamson PB, et al. Curr Heart Fail Reports, 2009.
GAIN IN TIME
Proactive and Actionable
Reactive and Inexact
Hemodynamically Stable Decompensation
HOSPITALIZATION
Autonomic Adaptation
Time Preceding Hospitalization (Days)
-30 -20 -10 0
Transthoracic Impedance
CHANGE
Filling Pressure
INCREASE
Weight Change
Symptoms
Presymptomatic Congestion
Hemodynamic Congestion
Clinical Congestion
Physical examTele monitoringDevice monitoringHemodynamic monitoring
![Page 94: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/94.jpg)
Intracardiac hemodynamics
Zile et al, Circulation
. 2008;118:1433-1441.
Chronicle device
![Page 95: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/95.jpg)
CardioMEMS™ HF System for the Management of HF• Delivers insight into the early onset of worsening HF to more proactively manage
HF patients and improve outcomes
95
• Abraham WT, Lancet, 2011.
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.
PULMONARY ARTERY PRESSURE
SENSOR
PATIENT ELECTRONICS
SYSTEM
MERLIN.NET™ PCN
TARGET LOCATION FOR PA PRESSURE SENSOR
![Page 96: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/96.jpg)
Microelectrical Mechanical System (MEMS)No lead or battery, no need for replacement
9625267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.
![Page 97: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/97.jpg)
The CardioMEMS™ HF System Implant Procedure• PA PRESSURE SENSOR IS INSERTED DURING A RIGHT HEART CATHETERIZATION
PROCEDURE VIA FEMORAL VEIN APPROACH.
9725267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.
![Page 98: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/98.jpg)
Pulmonary Artery Pressure
Medication Changes Based on Pulmonary Artery Pressure (p < 0.0001)
Pulmonary Artery Pressure Reduction (p = 0.008)
Reduction in Heart Failure Hospitalizations (p < 0.0001)
Quality of Life Improvement (p = 0.024)
MANAGING PRESSURES TO TARGET GOAL RANGES:
• PA pressure systolic 15–35 mmHg
• PA pressure diastolic 8–20 mmHg
• PA pressure mean 10–25 mmHg
Using diuretics and vasodilators, in addition to guideline-directed medical therapies
Summary of CHAMPION Randomized Clinical Trial:550 PREVIOUSLY HOSPITALIZED NYHA CLASS III PATIENTS
1. Abraham WT, et al. Lancet, 2011.
2. Abraham WT, et al. Lancet, 2016.
3. Adamson PB, et al. J Card Fail, 2010.
![Page 99: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/99.jpg)
Primary Efficacy Endpoint Met with Significantly Reduced Heart Failure Hospitalization• PART 1: RANDOMIZED ACCESS
99• Abraham W, et al. Lancet, 2016.
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
0 90 180 270 360 450 540 630 720 810 900 990 1080
Cu
mu
lati
ve H
azar
d R
ate
Days From Implant
33% RELATIVE RISK REDUCTION IN HF HOSPITALIZATIONS:TREATMENT GROUP VS. CONTROL GROUP
TREATMENT
CONTROL
No. at Risk
CONTROL 280 267 254 241 210 175 131 101 62 27 12 5 0
TREATMENT 270 262 246 235 197 164 125 105 75 38 8 3 0
p < 0.0001
![Page 100: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/100.jpg)
Both Primary Safety Endpoints Met
10025267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.
• 1167 patient-years of follow-up• 8 device/system-related complications (DSRC) • 0.007 DSRC per patient-year• All DSRC occurred within 30 days of implant• No sensor failures
No. at Risk 570 525 497 474 446 420 395 363 326 300 283 253 127 10 1
0 90 180 270 360 450 540 630 720 810 900 990 1080 1170 1260
Days from Implant Procedure
Fre
ed
om
fro
m D
evic
e/S
yste
m R
ela
ted
Co
mp
licat
ion
s (%
)
![Page 101: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/101.jpg)
All Secondary Endpoints Met
TREATMENT(N = 270)
CONTROL(N = 280)
P-VALUE
SECONDARYENDPOINTS
Change from baseline in PA mean pressure (mean AUC [mmHg x days])
-156 33 0.008
Number and proportion of patients hospitalized for HF (%)
55 (20%) 80 (29%) 0.03
Days alive and out of hospital for HF (mean ± SD)
174.4 ± 31.1
172.1 ± 37.8
0.02
Quality of life (Minnesota Living with Heart Failure Questionnaire, mean ± SD)
45 ± 26 51 ± 25 0.02
101
• *Total of 8 DSRCs including 2 events in Consented not implanted patients (n = 25)
• Abraham WT, et al. Lancet, 2011.
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.
PART 1: RANDOMIZED ACCESS PART 2: OPEN ACCESS
PART 1: RANDOMIZED ACCESS
![Page 102: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/102.jpg)
Real-world Use of the CardioMEMS™ HF System:ASSOCIATED HF HOSPITALIZATION COSTS
102
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.
$28,870
$47,690
$18,360
$34,500
$0K
$10K
$20K
$30K
$40K
$50K
$60K
$70K
$80K
6-MONTH COHORT 12-MONTH COHORT
Pre-Implant Post-Implant
-$10,510
-$13,190
Large (N = 1114) retrospective cohort study using the CardioMEMS™ HF System patients from CMS database
Desai, AS, et al. J Am Coll Cardiol, 2017;69(19):2357–65.
![Page 103: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/103.jpg)
Monitoring Pulmonary Artery Pressures,Proactive and Actionable
10325267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.• Adamson PB, et al. Curr Heart Fail Reports, 2009.
GAIN IN TIME
Proactive and Actionable
Reactive and Inexact
Hemodynamically Stable Decompensation
HOSPITALIZATION
Autonomic Adaptation
Time Preceding Hospitalization (Days)
-30 -20 -10 0
Transthoracic Impedance
CHANGE
Filling Pressure
INCREASE
Weight Change
Symptoms
Presymptomatic Congestion
Hemodynamic Congestion
Clinical Congestion
Physical examTele monitoring
![Page 104: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/104.jpg)
Monitoring Pulmonary Artery Pressures,Proactive and Actionable
10425267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.• Adamson PB, et al. Curr Heart Fail Reports, 2009.
GAIN IN TIME
Proactive and Actionable
Reactive and Inexact
Hemodynamically Stable Decompensation
HOSPITALIZATION
Autonomic Adaptation
Time Preceding Hospitalization (Days)
-30 -20 -10 0
Transthoracic Impedance
CHANGE
Filling Pressure
INCREASE
Weight Change
Symptoms
Presymptomatic Congestion
Hemodynamic Congestion
Clinical Congestion
Physical examTele monitoringDevice monitoring
![Page 105: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/105.jpg)
Monitoring Pulmonary Artery Pressures,Proactive and Actionable
10525267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.• Adamson PB, et al. Curr Heart Fail Reports, 2009.
GAIN IN TIME
Proactive and Actionable
Reactive and Inexact
Hemodynamically Stable Decompensation
HOSPITALIZATION
Autonomic Adaptation
Time Preceding Hospitalization (Days)
-30 -20 -10 0
Transthoracic Impedance
CHANGE
Filling Pressure
INCREASE
Weight Change
Symptoms
Presymptomatic Congestion
Hemodynamic Congestion
Clinical Congestion
Physical examTele monitoringDevice monitoringHemodynamic monitoring
![Page 106: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/106.jpg)
Information Overload
MA/Nurse APP/Physician
![Page 107: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/107.jpg)
Workflow
HF NP Reviews and adjusts treatment plan
EP njurse reviews and adjusts treatment EP Physician
HF physician
MA/Nurse reviews twice weekly initially and then prn for alerts
Patient transmits daily
![Page 108: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/108.jpg)
Virtual HF clinic-Key elements• Identify key team members
• Patient selection
• Policies and procedures for monitoring
• Establish workflows/Orders
• Staffing Buy in from other providersNetwork support for resources and staffing
• Alerts
• Keep medication changes on website
• Education
• Providers
• Patients
• Staff
![Page 109: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/109.jpg)
The End
![Page 110: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/110.jpg)
The CHAMPION Trial Subgroup Analyses
PROSPECTIVE ANALYSES:
• Effects of PAP pressure monitoring on:
– HFpEF subgroup
– HFrEF subgroup, HFrEF subgroup already on GDMT
11025267-SJM-MEM-0814-0012(1)a(9) | Item approved for global
use.
RETROSPECTIVE SUBGROUP ANALYSES:
• T h e r a p y g u i d e d b y PA P a l o n e v s . s i g n s a n d s y m p to m s
• M e d i c a r e - e l i g i b l e p o p u l a t i o n s
• PA - g u i d e d m e d i c a l m a n a g e m e n t
• H F p a t i e nt s w i t h c o m m o n c o m o r b i d i t i e s
![Page 111: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/111.jpg)
Treatment Group, HFpEF
Control Group, HFpEF
Prospective Subgroup Analysis: HFpEF PATIENTS MANAGED WITH THE CardioMEMS™ HF SYSTEM SHOW SIGNIFICANT REDUCTION IN HF Hospitalization
11125267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.
Avg. 18 months follow-up50% RRR, p < 0.0001
50 % reduction in HF Hospitalization
• Adamson PB, Abraham WT, Bourge RC, et al. Circ Heart Fail, 2014 Nov;7(6):935-44.
![Page 112: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/112.jpg)
Prospective Subgroup Analysis:HFrEF PATIENTS SHOWS SIGNIFICANT REDUCTION IN HF Hospitalization AND STRONG TREND TOWARDS IMPROVED SURVIVAL*
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.112
*The CardioMEMS™ HF System is not labeled for a reduction in mortality
Givertz M, et al. J Am Coll Cardiol, 2017.
Survival Probability
Kaplan-Meier Survival Analysis
Clinical OutcomesR
ates
Even
ts/P
atie
nt-
yr
TreatmentControl
0.69
0.24
Mortality RateHF Hospitalization Rate
0.49
0.18
p = 0.0013
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
0
28 % reduction
p = 0.06
Surv
ival
Pro
bab
ility
(%
)
No. at RiskCONTROL 234 209 173 102 45 7 0TREATMENT 222 202 161 105 62 7 0
32 % reduction
Treatment
Control
![Page 113: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/113.jpg)
Mortality
Dea
ths/
Pat
ien
t-yr
p = 0.0293
Retrospective Subgroup Analysis:HFrEF PATIENTS SHOW SYNERGY BETWEEN OPTIMAL GDMT AND HEMODYNAMIC CARE
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.113
HF
Ho
spit
aliz
atio
n/P
atie
nt-
yrp = 0.0002
HF Hospitalization
p = 0.0002
Dea
ths/
Pat
ien
t-yr
p = 0.0052
HF Hospitalization Mortality
Partial GDMT “Optimal” GDMT
33 % reduction
37 % reduction
43 % reduction
57 % reduction
*The CardioMEMS™ HF System is not labeled for a reduction in mortality
Givertz M, et al. J Am Coll Cardiol, 2017.
TreatmentControlTreatmentControl
HF
Ho
spit
aliz
atio
n/P
atie
nt-
yr
![Page 114: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/114.jpg)
Managing medical therapy based on PA pressures, along with follow-up lab and patient assessment led to SIGNIFICANTLY BETTER OUTCOMES THAN MANAGING BASED ON CLINICAL SIGNS AND SYMPTOMS
Managing GDMT Based on PA Pressures Alone Led to Significant Reduction in HF Hospitalization
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.114Goldberg, et al. HRS 2015.
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Clinical OnlyTriggered Rx
Clinical OnlyTriggered Rx
Clinical and PAP Triggered Rx
PAP OnlyTriggered Rx
HF Hospitalization Rate(Events/year)
1.17 1.22
0.63
0.39
p < 0.05
vs. Control Patients
Control Group - - - - - - - - - - - - - - - - - - - - - PAP Management Group - - - - - - - - - - - - - - - - - - - -
0.63p = 0.0007
vs. Control Patients
67 % RRR of HF Hospitalizations
![Page 115: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/115.jpg)
Subgroup Analysis: MEDICARE-ELIGIBLE POPULATION SHOWS SIGNIFICANT REDUCTION IN 30-DAY READMISSIONS
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.115Adamson, et al. Circ Heart Fail, 2016.
117
31
18
60
134
0
20
40
60
80
100
120
HF Hospitalizations All Cause 30 Day Readmissions HF 30 Day Readmissions
Nu
mb
er
of
Ho
spit
aliz
atio
ns
Eve
nts
/Pat
ien
t Ye
ar
Control (Standard of Care)
Treatment (PA Pressure Monitoring)
p = 0.0062 p = 0.0027p < 0.0001
STATISTICALLY SIGNIFICANT REDUCTIONS in 30-day readmission and HF Hospitalization in Medicare-eligible patients 65 years or older (n = 245), when PA pressures are monitored using the CardioMEMS™ HF System.
49 % reduction
58 % reduction 78 %
reduction
![Page 116: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/116.jpg)
Subgroup Analysis:HFrEF PATIENTS WITH CRT-D FOLLOWING GDMT
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.116Abraham, et al. HRS 2015.
64% reduction (p = 0.028)
![Page 117: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/117.jpg)
2468
1547
293 293 23996
1061
585
104 144 16068
0
500
1000
1500
2000
2500
All MedicationChanges
Diuretic (Loop orThiazide)
Vasodilator(Nitrate andHydralazine)
ACEI/ARB Beta Blocker AldosteroneAntagonist
Me
dic
atio
n C
han
ges
Frequency of Medication Changes by Drug Class
PA Pressure Guided HF Management(Treatment Group)
Standard of Care HF Management Only(Control Group)
Medication changes based on PA pressure information were MORE EFFECTIVE IN REDUCING HF HOSPITALIZATIONS than using signs and symptoms alone.
Subgroup Analysis: PA-GUIDED MEDICAL MANAGEMENT
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.117Costanzo, et al. J Am Coll Cardiol Heart Failure, 2016.
![Page 118: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/118.jpg)
Medication Increases and Decreases in Response to PAP
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.118
✽p < 0.05 PA Pressure Guided HF Management vs. Standard of Care HF Management
No Change represents where a medication was changed (ie., dose frequency, route, etc.) which resulted in no net dose equivalent change
Costanzo MR, et al. J Am Coll Cardiol HF, 2016.
0
250
500
750
1000
1250
1500
Med
icat
ion
Do
se In
crea
ses/
Dec
reas
es
fro
m B
ase
line
to 6
Mo
nth
s
PA Pressure Guided HF Management (Treatment Group)
Standard of Care HF Management Only (Control Group)
ALL MEDICATION
CHANGESDIURETIC (LOOP AND THIAZIDE)
VASODILATOR(NITRATE AND HYDRALAZINE) ACE/ARB BETA BLOCKER
ALDOSTERONEANTAGONIST
✽
✽✽
✽
✽
✽✽
![Page 119: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/119.jpg)
The CHAMPION Trial Subgroup Analyses: REDUCTION OF HF HOSPITALIZATION IN PATIENT GROUPS WITH COMMON COMORBIDITIES
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.119
1. Adamson, et al. Circ Heart Fail, 2016.
2. Adamson, et al. Circ Heart Fail, 2014.
3. Abraham, et al. ACC, 2015.
4. Abraham, et al. HRS 2015.
5. Strickland WL, et al. J Am Coll Cardiol, 2011.
6. Criner G, et al. Eur Respir J, 2012.
7. Martinez F, et al. Eur Respir J, 2012.
8. Benza R, et al. J Card Fail, 2012.
9. Miller AB, et al. J Am Coll Cardiol, 2012.
10.Abraham, et al. J Card Fail, 2014.
Sub-Group or Comorbidityn
(control)n
(treatment)Follow-up
Period (months)
Reduction of HF Hospitalization Rate in
Treatment Group vs. control
Medicare population1 125 120 18 49%, p < 0.0001
HFpEF2 56 59 18 50%, p < 0.0001
HFrEF following GDMT3 174 163 17 43%, p < 0.0001
CRT-D or ICD following GDMT4 146 129 18 43%, p < 0.0001
History of myocardial infarction5 137 134 15 46%, p < 0.001
COPD6,7 96 91 15 41%, p = 0.0009
Pulmonary hypertension8 163 151 15 36%, p = 0.0002
AF9 135 120 15 41%, p < 0.0001
Chronic kidney disease10 150 147 15 42%, p = 0.0001
Patients with common HF comorbidities and patients in important subgroups HAVE CONSISTENT REDUCTION IN HF HOSPITALIZATIONS with PA pressure-guided therapy.
![Page 120: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/120.jpg)
In the post-approval study, there were 56 HF Hospitalizations (0.20 events/pt-6m) in 43 pts
Reduction of HF Hospitalization in the CardioMEMS™
HF System Post-Approval Study
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.120
0
20
40
60
80
100
120
0 30 60 90 120 150 180
Cu
mu
lati
ve H
F H
osp
ital
izat
ion
s
Days from Implant
CHAMPION Control CHAMPION Treatment Post-Approval Study
Raval, et al. Presented at HFSA 2017.
![Page 121: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/121.jpg)
1226
718
244172
660
341
169
45
0
200
400
600
800
1000
1200
1400
Total Up Titrations Down Titrations New
Nu
mb
er o
f M
edic
atio
n C
han
ges
Medication Changes – First 90 days vs. second 90 days
First 90 Days
Second 90 Days
Medication Changes Significantly Reduced in First 90 Days vs. Second 90 Days in the PAS
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.121Raval, et al. Presented at HFSA 2017.
p < 0.0004 p < 0.0004 p = 0.0008 p < 0.0004
46 % reduction
53% reduction
31% reduction 74%
reduction
65% of the overall HF medication changes were made in the first 90 days, with trends of stabilization and significantly fewer medication changes during the second 90 days.
![Page 122: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/122.jpg)
The CardioMEMS™ HF System PAS Short-term ResultsREDUCED HF Hospitalization AND MEAN PAP
12225267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.Raval, et al. Presented at HFSA 2017.
AUC (mmHg day)
1 Month 3 Months 6 Months
CHAMPION Control
(275 pts)
3.1 ± 6.7
(270 pts)
-5.5 ± 24.7
(251 pts)
42.0 ± 65.0
(228 pts)
CHAMPION
Treatment (270 pts)
-7.0 ± 7.7
(266 pts)
-59.3 ± 27.6
(257 pts)
-150.1 ± 71.0
(236 pts)
PAS
(300 pts)
-27.7 ± 7.0
(291 pts)
-112.6 ± 26.0
(275 pts)
-281.0 ± 63.5
(262 pts)
SIGNIFICANTLY GREATER REDUCTIONS IN MEAN PAP for the PAS cohort relative to the CHAMPION control group after 6 months, and QUALITATIVELY GREATER REDUCTIONS compared to the CHAMPION treatment group.
CHAMPION Control
CHAMPION Treatment
Post Approval Study
Short-term Cohort(n = 300)
p =
0.0
47
6
p <
0.0
00
1
![Page 123: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/123.jpg)
EF ≥ 40
EF < 40
Pressures are Reduced Equally Well in HFrEF and HFpEF, as well as Male and Female
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.123
AUC Mean PAP Stratified by Ejection Fraction AUC Mean PAP Stratified by Gender
Heywood JT, Jermyn R, Shavelle D, et al. Circulation 2017;135: 1509–17.
Female
Male
![Page 124: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/124.jpg)
Pressure Changes Stratified by Baseline PA Pressure
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.124
.
Heywood JT, Jermyn R, Shavelle D, et al. Circulation 2017;135: 1509–17.
Greatest reduction in mean PAP observed for the CardioMEMS™ HF System patients with higher baseline PAP.
Patients in the treatment group with baseline PAP at goal, remained at goal over time.
Baseline meanPAP < 25 mmHg 35 > Baseline meanPAP ≥ 25 mmHg Baseline meanPAP ≥ 35 mmHg
![Page 125: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/125.jpg)
Real-world Use of the CardioMEMS™ HF System:REDUCED HF HOSPITALIZATIONS
125
Large (N = 1114) retrospective cohort study using the CardioMEMS™ HF System patients from CMS database
Desai, AS, et al. J Am Coll Cardiol, 2017;69(19):2357–65. 25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.
Cumulative HF Hospitalization During Period Before and After CardioMEMS™ HF System Implant
45% reductionat 6 months (p < 0.001)
Pre-implant
Post-implant
PRE-IMPLANT 0 -1 -2 -3 -4 -5 -6
POST-IMPLANT 0 +1 +2 +3 +4 +5 +6
Time (months)
![Page 126: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/126.jpg)
Real-world Use of the CardioMEMS™ HF System:ASSOCIATED HF HOSPITALIZATION COSTS
126
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.
$28,870
$47,690
$18,360
$34,500
$0K
$10K
$20K
$30K
$40K
$50K
$60K
$70K
$80K
6-MONTH COHORT 12-MONTH COHORT
Pre-Implant Post-Implant
-$10,510
-$13,190
Large (N = 1114) retrospective cohort study using the CardioMEMS™ HF System patients from CMS database
Desai, AS, et al. J Am Coll Cardiol, 2017;69(19):2357–65.
![Page 127: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/127.jpg)
Northwell Health: SIGNIFICANT IMPROVEMENT IN FC AND QoL IN PATIENTS IMPLANTED WITH THE CardioMEMS™ HF SYSTEM
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.127Alam A, et al. Abstract presented at ACC, 2016.
6-minute walk: Avg. increase of 96 meters at 90 days versus no increase in the SoC group
0
100
200
300
400
CardioMEMS™ PA Sensor (n = 34) Control (n = 32)
Dis
tan
ce (
m)
Baseline
30 days
90 days
0
20
40
60
80
100
CardioMEMS (n = 34) Control (n = 32)
Sco
re Baseline
90 days
KCCQ: 3-fold greater improvement in scores
p < 0.001 compared to baseline
p < 0.001 p = 0.003
![Page 128: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/128.jpg)
128
• The CardioMEMS™ HF System is safe, reliable and clinically proven in clinical trials and real-world settings.
• It provides a proactive, personalized approach to prevent acute decompensation in both HFrEF and HFpEF patients.
25267-SJM-MEM-0814-0012(1)a(9) | Item approved for global use.
CONCLUDING SUMMARY
![Page 129: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/129.jpg)
Panel Discussion: Clinical Care Management Studies
Acute Heart Failure, Cardiorenal Syndrome, Evolution to HFpEF
![Page 130: Congestive Heart Failure: Turning Failure Into Success · TRIAL N PARAMETER MONITORED IMPACT ON HF HOSPITALIZATION JOURNAL TELE-HF1 1,653 Signs/symptoms, daily weights None The New](https://reader034.vdocuments.net/reader034/viewer/2022042412/5f2c7cf62de38b6420623093/html5/thumbnails/130.jpg)
Closing RemarksJayne Testa, CMPE
Kettering Heart & Vascular Executive Director